Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
<b>Context:</b> Increased vascular cell adhesion molecule-1 (VCAM-1) has been reported to be a critical link between obesity and atherosclerotic cardiovascular diseases while dipeptidyl peptidase-4 (DPP-4) has been implicated in the development of disrupted glucose regulation and inflammation.
|
31387411 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase-4 (DPP-4) inhibitors have been shown to have a protective effect on cardiovascular disease.
|
25876091 |
2015 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase-4 inhibitors might have pleiotropic protective effects on cardiovascular disease (CVD), in contrast to sulfonylureas.
|
27575011 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase IV (DPP-IV) has been revealed as an adipokine with potential relevance in cardiovascular disease (CVD), while clinically used DPP-IV inhibitors have demonstrated beneficial cardiovascular effects in several experimental studies.
|
28697993 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase 4 inhibitors are used worldwide in the management of diabetes, but their role in the prevention or treatment of cardiovascular disorders has yet to be defined.
|
28771625 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dipeptidyl peptidase IV (DPP-4) is well known for its role in glucose homeostasis, and DPP-4 inhibitor (DPP-4i) exhibits multiple actions in cardiovascular diseases.
|
29789684 |
2018 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A decreased risk of hospitalization for CVDs was found among patients with a history of visit for CVDs (aHR, 0.73; 95% CI, 0.56-0.97) or with >2.5 years' duration of type 2 diabetes (aHR, 0.77; 95% CI, 0.66-0.91) in the DPP-4 inhibitors versus glimepiride group.DPP-4 inhibitors did not increase cardiovascular risk compared with glimepiride regardless of CVD history and diabetes duration.
|
28640111 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Among them, the sodium-glucose co-transporter-2 (SGLT-2) inhibitors (gliflozins) and selected agents from the incretin mimetics or enhancers, such as the glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins), appear to confer cardiovascular safety and/or protection in patients with underlying, or at high risk for, cardiovascular disease.
|
30251174 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis.
|
21558879 |
2011 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review.
|
27813442 |
2017 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Combination therapy of metformin plus dipeptidyl peptidase-4 inhibitor versus metformin plus sulfonylurea and their association with a decreased risk of cardiovascular disease in type 2 diabetes mellitus patients.
|
28885325 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, dipeptidyl peptidase 4 (DPP-4) inhibitors did not significantly affect atherosclerotic CVD end-points and some actually increased the risk of HF hospitalizations.
|
31442511 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dapagliflozin was associated with a lower risk of both all-cause mortality and CVD, whereas DPP-4 inhibitor treatment was only associated with lower risk of all-cause mortality.
|
28116795 |
2017 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Evaluation of large-scale clinical trials on cardiovascular disease risk in patients with type 2 diabetes mellitus treated with dipeptidyl peptidase 4 inhibitors and a new class of drugs.
|
28130883 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition to T2DM, a regulatory role of DPP-4 was also found in cardiovascular diseases.
|
31390221 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In fully adjusted models, use of SGLT2 inhibitors was associated with a decreased risk of developing CVD compared with use of sulfonylureas (HR, 0.50; 95% CI, 0.45, 0.55) and DPP-4 inhibitors (HR, 0.57; 95% CI, 0.52, 0.62), respectively.
|
30039524 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In the cardiovascular outcome trials (CVOT) EMPA-REG OUTCOME, TECOS and SAVOR-TIMI 53, empagliflozin [sodium/glucose cotransporter 2 (SGLT2) inhibitor], sitagliptin and saxagliptin [both dipeptidyl peptidase 4 (DPP4) inhibitors] + standard of care (SoC) were compared to SoC in patients with type 2 diabetes and established cardiovascular disease (CVD).
|
31602601 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present review, we discuss the GLP-1 (glucagon-like peptide-1) receptor agonists and DPP-4 (dipeptidyl peptidase-4) inhibitors (incretin-based therapies), which are novel antidiabetic agents used in clinical practice and their role in diabetic nephropathy with specific focus on renoprotection and surrogate markers of cardiovascular disease.
|
22963445 |
2013 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Indeed, DPP-IV is upregulated in proinflammatory states, including obesity and cardiovascular disease with and without diabetes mellitus.
|
28344207 |
2017 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inhibitors of dipeptidyl peptidase-IV (DPP-IV), which decrease the degradation of glucose-lowering GLP-1(7-36) to the metabolically inactive GLP-1(9-36), are current new treatment options for patients with type 2 diabetes mellitus, a high-risk population for cardiovascular disease.
|
23469279 |
2013 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that DPP-4 may become a new therapeutic target for chronic stress-related vascular aging in metabolic cardiovascular diseases.
|
31586451 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Recently, the dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin, a major anti-hyperglycaemic agent, has received substantial attention as a therapeutic target for cardiovascular diseases via enhancing the number of circulating endothelial progenitor cells (EPCs).
|
28799229 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Some protective effects of DPP-4 on cardiovascular disease have been described independently from glucose-lowering effect.
|
28923269 |
2017 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The large trials evaluating the dipeptidyl peptidase-4 inhibitors sitagliptin, alogliptin and saxagliptin demonstrated safety for cardiovascular disease.
|
31018682 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The objective of this nationwide study was to compare the risk of all-cause mortality, fatal and nonfatal cardiovascular disease (CVD), and severe hypoglycemia in patients with type 2 diabetes (T2D) on metformin monotherapy treatment starting second-line treatment with either insulin or dipeptidyl peptidase-4 inhibitor (DPP-4i).
|
28056431 |
2017 |